Treatment of systemic-onset juvenile arthritis with canakinumab

Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Peitz, Joachim, Horneff, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045123/
https://www.ncbi.nlm.nih.gov/pubmed/27790042
http://dx.doi.org/10.2147/OARRR.S54215
_version_ 1782457059879419904
author Peitz, Joachim
Horneff, Gerd
author_facet Peitz, Joachim
Horneff, Gerd
author_sort Peitz, Joachim
collection PubMed
description Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.
format Online
Article
Text
id pubmed-5045123
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50451232016-10-27 Treatment of systemic-onset juvenile arthritis with canakinumab Peitz, Joachim Horneff, Gerd Open Access Rheumatol Review Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis. Dove Medical Press 2015-02-18 /pmc/articles/PMC5045123/ /pubmed/27790042 http://dx.doi.org/10.2147/OARRR.S54215 Text en © 2015 Peitz and Horneff. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Peitz, Joachim
Horneff, Gerd
Treatment of systemic-onset juvenile arthritis with canakinumab
title Treatment of systemic-onset juvenile arthritis with canakinumab
title_full Treatment of systemic-onset juvenile arthritis with canakinumab
title_fullStr Treatment of systemic-onset juvenile arthritis with canakinumab
title_full_unstemmed Treatment of systemic-onset juvenile arthritis with canakinumab
title_short Treatment of systemic-onset juvenile arthritis with canakinumab
title_sort treatment of systemic-onset juvenile arthritis with canakinumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045123/
https://www.ncbi.nlm.nih.gov/pubmed/27790042
http://dx.doi.org/10.2147/OARRR.S54215
work_keys_str_mv AT peitzjoachim treatmentofsystemiconsetjuvenilearthritiswithcanakinumab
AT horneffgerd treatmentofsystemiconsetjuvenilearthritiswithcanakinumab

Ejemplares similares